PRL and Increased circulating prolactin concentration: Thus, activation of hypothalamic dopaminergic neurotransmission by dopamine agonists can reduce incidence and prevalence of MetS in patients with hyperprolactinaemia by controlling of PRL release and improving of insulin sensitivity.88